Isometric contraction induces the Ca2+-independent activation of the endothelial nitric oxide synthase

Proc Natl Acad Sci U S A. 1999 Feb 2;96(3):1123-8. doi: 10.1073/pnas.96.3.1123.

Abstract

Shear stress and tyrosine phosphatase inhibitors have been shown to activate the endothelial NO synthase (eNOS) in a Ca2+/calmodulin-independent manner. We report here that isometric contraction of rabbit aorta activates eNOS by a pharmacologically identical pathway. Endothelium-intact aortic rings were precontracted under isometric conditions up to 60% of the maximal phenylephrine-induced tone. The NO synthase inhibitor NGnitro-L-arginine (L-NA) and the soluble guanylyl cyclase inhibitor NS 2028 induced an additional contraction, the amplitude of which depended on the level of precontraction. The maximal production of NO by isometrically contracted aortic rings (as estimated by the increase in cGMP in detector smooth muscle cells in a superfusion bioassay) was observed during the initial phase of isometric contraction and was greater than that detected following the application of acetylcholine. The supplementary L-NA-induced increase in vascular tone was inhibited by the nonselective kinase inhibitor staurosporine and the tyrosine kinase inhibitors erbstatin A and herbimycin A. Another tyrosine kinase inhibitor, genistein, the calmodulin antagonist calmidazolium, and the selective protein kinase C inhibitor, Ro 31-8220, had no effect. Coincident with the enhanced NO formation during isometric contraction was an increase in the tyrosine phosphorylation of endothelial proteins, which also correlated with the level of precontraction. Thus, isometric contraction activates eNOS via a Ca2+-independent, tyrosine kinase inhibitor-sensitive pathway and, like shear stress, seems to be an independent determinant of mechanically induced NO formation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 1-Methyl-3-isobutylxanthine / pharmacology
  • Acetylcholine / pharmacology
  • Animals
  • Aorta, Thoracic / drug effects
  • Aorta, Thoracic / physiology*
  • Benzoquinones
  • Calcium / metabolism
  • Calmodulin / antagonists & inhibitors
  • Cells, Cultured
  • Cyclic GMP / metabolism*
  • Endothelium, Vascular / drug effects
  • Endothelium, Vascular / physiology*
  • Enzyme Activation
  • Enzyme Inhibitors / pharmacology
  • Female
  • Genistein / pharmacology
  • Hydroquinones / pharmacology
  • Imidazoles / pharmacology
  • In Vitro Techniques
  • Indoles / pharmacology
  • Isometric Contraction / drug effects
  • Isometric Contraction / physiology*
  • Lactams, Macrocyclic
  • Male
  • Muscle, Smooth, Vascular / drug effects
  • Muscle, Smooth, Vascular / physiology*
  • Nitric Oxide Synthase / metabolism*
  • Nitric Oxide Synthase Type III
  • Nitroarginine / pharmacology*
  • Oxadiazoles / pharmacology
  • Oxazines / pharmacology
  • Quinones / pharmacology
  • Rabbits
  • Rifabutin / analogs & derivatives
  • Staurosporine / pharmacology

Substances

  • Benzoquinones
  • Calmodulin
  • Enzyme Inhibitors
  • Hydroquinones
  • Imidazoles
  • Indoles
  • Lactams, Macrocyclic
  • NS 2028
  • Oxadiazoles
  • Oxazines
  • Quinones
  • Rifabutin
  • Nitroarginine
  • calmidazolium
  • herbimycin
  • Genistein
  • Nitric Oxide Synthase
  • Nitric Oxide Synthase Type III
  • Cyclic GMP
  • Staurosporine
  • Acetylcholine
  • Calcium
  • 1-Methyl-3-isobutylxanthine
  • Ro 31-8220
  • erbstatin